Hill N C, Selinger M, Ferguson J, MacKenzie I Z
Nuffield Department of Obstetrics and Gynaecology, University of Oxford, John Radcliffe Hospital, UK.
Int J Gynaecol Obstet. 1991 Aug;35(4):337-40. doi: 10.1016/0020-7292(91)90668-u.
PGE1 analogue (gemeprost) vaginal pessaries administered three hourly for three doses has been compared with a single extra- or intra-amniotic injection of PGE2 for mid-trimester termination of pregnancy in 450 women between 13 and 20 weeks gestation. The mean (SD) induction-abortion interval (IAI) in the vaginal pessary group of 19.5 (8.4) h was significantly longer than the respective intervals of 14.4 (9.3) and 16.1 (6.8) h in the patients treated extra- or intra-amniotically (P less than 0.001). Seventy-three percent treated with gemeprost aborted within 24 h of initial treatment compared with 84% and 87%, respectively in the extra- and intra-amniotic groups (P less than 0.05). Patients treated with gemeprost were more likely to need further prostaglandin treatment and had an increased incidence of gastrointestinal side effects. Despite these differences vaginal gemeprost pessaries provide a safe, effective, easy to administer method for midtrimester termination of pregnancy.
对妊娠13至20周的450名妇女进行了研究，比较了每三小时阴道给药一次、共给药三次的前列腺素E1类似物（吉美前列素）阴道栓剂与单次羊膜外或羊膜腔内注射前列腺素E2用于中期妊娠终止的效果。阴道栓剂组的平均（标准差）引产-流产间隔时间（IAI）为19.5（8.4）小时，显著长于羊膜外或羊膜腔内治疗患者的相应间隔时间14.4（9.3）小时和16.1（6.8）小时（P<0.001）。接受吉美前列素治疗的患者中有73%在初始治疗后24小时内流产，而羊膜外组和羊膜腔内组分别为84%和87%（P<0.05）。接受吉美前列素治疗的患者更有可能需要进一步的前列腺素治疗，且胃肠道副作用发生率增加。尽管存在这些差异，但阴道用吉美前列素栓剂为中期妊娠终止提供了一种安全、有效且易于给药的方法。
